Cipher Pharmaceuticals Inc.
CPH.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 104.86% | 140.28% | 70.90% | 0.30% | 20.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 104.86% | 140.28% | 70.90% | 0.30% | 20.08% |
| Cost of Revenue | 172.89% | 437.07% | 83.09% | 4.24% | 7.98% |
| Gross Profit | 89.94% | 68.80% | 68.27% | -0.69% | 23.10% |
| SG&A Expenses | 228.54% | 274.65% | 172.49% | 4.36% | 24.51% |
| Depreciation & Amortization | 530.45% | 453.48% | 615.61% | -14.62% | -15.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 239.44% | 350.33% | 179.15% | -1.70% | 12.39% |
| Operating Income | -19.02% | -85.90% | -38.14% | 2.49% | 28.15% |
| Income Before Tax | -36.42% | -177.53% | -89.56% | -20.66% | 9.60% |
| Income Tax Expenses | 62.30% | -55.96% | 101.10% | -584.85% | -2,484.15% |
| Earnings from Continuing Operations | -46.70% | -56.32% | -95.97% | -2.47% | 87.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.70% | -56.32% | -95.97% | -2.47% | 87.47% |
| EBIT | -19.02% | -85.90% | -38.14% | 2.49% | 28.15% |
| EBITDA | 28.47% | -34.55% | 15.28% | 0.45% | 22.63% |
| EPS Basic | -50.05% | -58.81% | -95.97% | 2.48% | 96.18% |
| Normalized Basic EPS | -36.35% | -151.27% | -38.78% | -13.59% | 13.18% |
| EPS Diluted | -50.00% | -57.17% | -96.30% | 0.00% | 100.00% |
| Normalized Diluted EPS | -36.71% | -152.37% | -39.00% | -13.80% | 13.10% |
| Average Basic Shares Outstanding | 6.74% | 6.05% | -0.53% | -4.84% | -4.47% |
| Average Diluted Shares Outstanding | 7.41% | 3.81% | -0.02% | -4.49% | -4.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |